Corcept Therapeutics (NASDAQ:CORT) Price Target Cut to $60.00 by Analysts at HC Wainwright

Corcept Therapeutics (NASDAQ:CORT) had its price objective decreased by HC Wainwright from $67.00 to $60.00 in a report published on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

Other analysts have also issued reports about the stock. Zacks Research lowered shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Truist Financial set a $50.00 target price on shares of Corcept Therapeutics in a research note on Wednesday, December 31st. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target for the company. in a research report on Wednesday, December 31st. Weiss Ratings reissued a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. Finally, UBS Group initiated coverage on shares of Corcept Therapeutics in a report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $76.00.

Corcept Therapeutics Trading Up 19.7%

CORT opened at $40.47 on Wednesday. The stock has a market capitalization of $4.30 billion, a PE ratio of 49.35 and a beta of 0.29. Corcept Therapeutics has a one year low of $28.66 and a one year high of $117.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92. The business’s 50 day moving average price is $37.41 and its 200 day moving average price is $61.15.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The business had revenue of $202.13 million during the quarter, compared to analysts’ expectations of $254.94 million. During the same quarter in the prior year, the firm earned $0.26 EPS. Corcept Therapeutics’s revenue for the quarter was up 11.1% compared to the same quarter last year. As a group, equities research analysts expect that Corcept Therapeutics will post 1.36 EPS for the current year.

Insider Transactions at Corcept Therapeutics

In other news, Director G Leonard Baker, Jr. bought 100,000 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was bought at an average cost of $33.14 per share, with a total value of $3,314,000.00. Following the transaction, the director directly owned 1,146,631 shares in the company, valued at $37,999,351.34. The trade was a 9.55% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider William Guyer sold 20,000 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $40.87, for a total transaction of $817,400.00. Following the sale, the insider owned 1,235 shares in the company, valued at $50,474.45. This trade represents a 94.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 60,000 shares of company stock valued at $2,241,035 over the last 90 days. 20.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Corcept Therapeutics

Large investors have recently added to or reduced their stakes in the business. Pathstone Holdings LLC lifted its holdings in Corcept Therapeutics by 0.8% during the 3rd quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock worth $1,497,000 after buying an additional 144 shares in the last quarter. Campbell Newman Asset Management Inc. grew its stake in shares of Corcept Therapeutics by 0.5% in the third quarter. Campbell Newman Asset Management Inc. now owns 35,530 shares of the biotechnology company’s stock worth $2,953,000 after acquiring an additional 170 shares in the last quarter. Clearstead Advisors LLC increased its position in shares of Corcept Therapeutics by 163.6% during the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 193 shares during the period. Gould Capital LLC raised its stake in shares of Corcept Therapeutics by 50.0% in the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 200 shares in the last quarter. Finally, Advisors Asset Management Inc. raised its stake in shares of Corcept Therapeutics by 1.3% in the second quarter. Advisors Asset Management Inc. now owns 18,935 shares of the biotechnology company’s stock valued at $1,390,000 after acquiring an additional 237 shares in the last quarter. 93.61% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel for platinum‑resistant ovarian cancer — key commercial catalyst and the immediate driver of the rally; approval was completed ahead of schedule and trial data showed a survival benefit. FDA Approves Corcept’s Lifyorli (BusinessWire)
• Positive Sentiment: Coverage/analyst support: H.C. Wainwright reiterated a Buy and published a $60 price target (lowered from $67) while calling the early approval and long‑term sales outlook supportive — helps justify upside expectations despite the lower PT. Corcept Wins FDA Approval (TipRanks)
• Positive Sentiment: Insider/director buying noted in mid‑March (100,000 shares) has been cited by market commentary as a confidence signal and likely amplified bullish positioning ahead of the approval. Insider Buy & Catalyst Analysis (QuiverQuant)
• Neutral Sentiment: Trading was temporarily halted earlier today for a LULD pause as the stock moved sharply — a market‑structure response to volatility, not company news. (Trading halt reported in market feeds.)
• Neutral Sentiment: Some outlets reported very large intraday moves (30–48%+ intraday prints) as traders re‑priced the stock on the approval; expect continued volatility and large volume in the near term. Market Reaction Coverage (Reuters)
• Negative Sentiment: Multiple law firms have filed/alerted investors about securities‑class‑action suits alleging prior disclosures and regulatory/patent issues — these lawsuits and related allegations (including references to an FDA rejection and court patent loss in filings) represent material legal and financial risk that could pressure the stock. Hagens Berman Securities Class Action Alert (GlobeNewswire)
• Negative Sentiment: Recent insider selling: a disclosed sale by William Guyer on March 20 reduces insider ownership and may be viewed unfavorably by some investors (though offset by the director buy referenced above). Insider Sale SEC Filing

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.